Abexinostat is an investigational pan-histone deacetylase (HDAC) inhibitor under clinical evaluation for lymphoma and various solid tumours, working by modulating chromatin acetylation to restore tumour-suppressor gene expression. Its status as an emerging oncology candidate makes well-defined reference material valuable for research and early-stage analytical work. Simson Pharma supplies an Abexinostat reference standard to support such R&D and method-development needs.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Abexinostat Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.